Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 566 clinical trials
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT. The time from SCT to the initiation of VELCADE treatment will be 3 to 6 months.

velcade
cell transplantation
melphalan
remission
bortezomib
  • 16 views
  • 07 Nov, 2020
  • 7 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG)

. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell

  • 18 views
  • 13 Mar, 2021
  • 14 locations
Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen

Analyze the results of ASCT using intravenous Busulfan and Melphalan as conditioning regimen for patients with Multiple Myeloma.

line of therapy
melphalan
transplant conditioning
busulfan
bortezomib
  • 14 views
  • 07 Nov, 2020
  • 5 locations
TCD Followed by autoSCT for Newly Diagnosed MM Patients

Multiple Myeloma is a incurable disease. Thalidomide in combination with other agents are currently in trials for the newly diagnosed patients, we designed treatment of TCD, followed by

cell transplantation
thalidomide
maintenance therapy
high dose chemotherapy
  • 5 views
  • 07 Nov, 2020
  • 1 location
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

first line treatment for the patients with multiple myeloma 2. Secondary Objectives 1. To assess the progression free survival, duration of response, and overall

velcade
cell transplantation
dexamethasone
induction therapy
platelet count
  • 7 views
  • 07 Nov, 2020
  • 1 location
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Myeloma. The second phase of the study will establish whether depsipeptide, bortezomib and dexamethasone is effective in the treatment of patients with multiple myeloma. The study will also

plasmacytoma
dexamethasone
measurable disease
platelet count
monoclonal antibodies
  • 31 views
  • 07 Nov, 2020
  • 1 location
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

CART therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with high risk multiple myeloma after

  • 37 views
  • 29 May, 2021
  • 1 location
  • 0 views
  • 26 Jan, 2021
  • 1 location
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction Follow by Dara Consolidation

The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo. Nevertheless, until now four

  • 0 views
  • 22 Jan, 2021
  • 1 location
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.

  • 0 views
  • 26 Jan, 2021
  • 1 location